CN112715729A - 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 - Google Patents
一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 Download PDFInfo
- Publication number
- CN112715729A CN112715729A CN202011601006.6A CN202011601006A CN112715729A CN 112715729 A CN112715729 A CN 112715729A CN 202011601006 A CN202011601006 A CN 202011601006A CN 112715729 A CN112715729 A CN 112715729A
- Authority
- CN
- China
- Prior art keywords
- lutein ester
- blueberry
- citric acid
- candy
- maltodextrin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 title claims abstract description 69
- 235000003095 Vaccinium corymbosum Nutrition 0.000 title claims abstract description 52
- 235000017537 Vaccinium myrtillus Nutrition 0.000 title claims abstract description 52
- 235000021014 blueberries Nutrition 0.000 title claims abstract description 52
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 45
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 244000077233 Vaccinium uliginosum Species 0.000 title description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 90
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 49
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 40
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 32
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 23
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 23
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 23
- 239000000843 powder Substances 0.000 claims abstract description 21
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 20
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 14
- 238000007873 sieving Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 239000007779 soft material Substances 0.000 claims abstract description 10
- 229960004106 citric acid Drugs 0.000 claims description 29
- 238000001035 drying Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 229940057948 magnesium stearate Drugs 0.000 claims description 5
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 3
- 240000000785 Tagetes erecta Species 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003094 microcapsule Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- YHGJHDJZIOYZIR-KFTCWRDFSA-N Helenien Natural products O=C(O[C@H]1C=C(C)[C@H](/C=C/C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=2C(C)(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC=2C)\C)/C)\C)/C)C(C)(C)C1)CCCCCCCCCCCCCCC YHGJHDJZIOYZIR-KFTCWRDFSA-N 0.000 claims description 2
- YHGJHDJZIOYZIR-UHFFFAOYSA-N all-trans-lutein dipalmitate Natural products CC1(C)CC(OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1C(C)(C)CC(OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-UHFFFAOYSA-N 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- -1 lutein dipalmitate ester Chemical class 0.000 claims description 2
- 235000013305 food Nutrition 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 238000009776 industrial production Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 14
- 235000003599 food sweetener Nutrition 0.000 description 10
- 239000003765 sweetening agent Substances 0.000 description 10
- 235000010208 anthocyanin Nutrition 0.000 description 9
- 239000004410 anthocyanin Substances 0.000 description 9
- 229930002877 anthocyanin Natural products 0.000 description 9
- 150000004636 anthocyanins Chemical class 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 7
- 235000012680 lutein Nutrition 0.000 description 7
- 239000001656 lutein Substances 0.000 description 7
- 229960005375 lutein Drugs 0.000 description 7
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 7
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 208000002177 Cataract Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000003405 preventing effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 206010015967 Eye swelling Diseases 0.000 description 2
- 206010034960 Photophobia Diseases 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940107604 lutein esters Drugs 0.000 description 2
- 150000002658 luteins Chemical class 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000004379 myopia Effects 0.000 description 2
- 208000001491 myopia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 102000014824 Crystallins Human genes 0.000 description 1
- 108010064003 Crystallins Proteins 0.000 description 1
- RKWHWFONKJEUEF-GQUPQBGVSA-O Cyanidin 3-O-glucoside Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 RKWHWFONKJEUEF-GQUPQBGVSA-O 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- YHGJHDJZIOYZIR-URPSFYETSA-N Helenien Chemical compound CC1(C)C[C@H](OC(=O)CCCCCCCCCCCCCCC)CC(C)=C1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@@H]1C(C)(C)C[C@@H](OC(=O)CCCCCCCCCCCCCCC)C=C1C YHGJHDJZIOYZIR-URPSFYETSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- YTMNONATNXDQJF-UBNZBFALSA-N chrysanthemin Chemical compound [Cl-].O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC2=C(O)C=C(O)C=C2[O+]=C1C1=CC=C(O)C(O)=C1 YTMNONATNXDQJF-UBNZBFALSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000004423 myopia development Effects 0.000 description 1
- 229960004760 naphazoline hydrochloride Drugs 0.000 description 1
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 description 1
- 229960002253 neostigmine methylsulfate Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical compound Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004436 pseudomyopia Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940021790 tetrahydrozoline hydrochloride Drugs 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法,按重量份数计,所述蓝莓叶黄素酯压片糖果包括以下组分:叶黄素酯5~30%、蓝莓粉10~60%、D‑甘露糖醇10~70%、麦芽糊精5~30%、微晶纤维素0~10%、柠檬酸0~1.5%、硬脂酸镁0‑1%;所述制备方法包括过筛、混合、制软材、制粒、总混、压片等步骤。本发明通过叶黄素酯、蓝莓粉等原料组分的协同配合作用,能够显著缓解视疲劳,采用所述制备方法制成当前接受度普遍较高的日常零食品之一的压片糖果,方便食用及携带,并具有良好的口感,且制备方法操作简单,流程简化,能够满足大规模工业化生产应用。
Description
技术领域
本发明涉及保健功能食品技术领域,具体涉及一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法。
背景技术
视疲劳又称为眼疲劳,是一种由多种原因导致的用眼不持久或长时间用眼后出现眼部不适、视觉障碍、疲倦等症状的疾病,目前以患者自觉眼部症状为主。视疲劳无器质性病变,与用眼习惯、社会环境和自身体质等有关,临床主要表现为眼痛、眼胀、眼干、视物模糊、畏光、异物感、视力不稳定等,亦可合并全身及精神症状,如头痛、失眠、腰背酸痛、记忆力衰退等。
受生活节奏和工作压力的影响,人群中用眼时长普遍延长、强度加大,近年来视疲劳的发生有明显上升。研究发现,引起视疲劳的因素包括荧屏光暴露、不良用眼习惯、近视相关等。长期荧屏光暴露是视疲劳的危险因素,可能与荧屏暴露造成眼部调节作用降低导致视疲劳有关,而叶黄素摄入和户外活动是视疲劳发生的保护因素。Yoshioka等学者的实验表明,视疲劳与电脑屏幕暴露时间及睡眠质量等两者存在明显的关联,并且电脑屏幕暴露如果每天大于6小时,则呈现为显著的线性相关。不良用眼习惯如长期用眼过度、不良环境用眼均可增加视疲劳危险,在不良环境中用眼可引起泪液分泌降低、泪膜稳定性不足,较易引起视疲劳。
针对视疲劳所出现的一系列问题,现在市面上有很多相关护眼治疗的仪器、药物和保健品等。物理方法虽然在一定程度上缓解了视疲劳,但是对眼睛本身造成的损伤却无法修复,无法安全有效解决大部分当代人存在的光辐射等因素造成的眼部损伤;而且,大多数药物中含有毒素或是带有副作用,如眼药水中的成分盐酸萘甲唑啉、盐酸羟甲唑啉、盐酸四氢唑林会导致瞳孔散大,甚至导致闭角型青光眼急性发作,导致血管更粗大、舒张更明显,容易产生依赖。甲基硫酸新斯的明能勉强使睫状肌继续工作,但会导致疲劳更难缓解,假性近视的人滥用这类药物,可能加速近视发展;除此之外,相关药物或保健品的辅料添加不科学,如添加了白砂糖等不利于青少年防龋齿及老年糖尿病患者的治疗,味道不适口等问题。
发明内容
为解决上述技术问题,本发明旨在提供一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法,所述蓝莓叶黄素酯压片糖果能够改善荧屏光暴露、不良用眼习惯、近视等引起的视疲劳。
为达到上述目的,本发明提供如下技术方案:
一种缓解视疲劳的蓝莓叶黄素酯压片糖果,包括以下组分:叶黄素酯、蓝莓粉、D-甘露糖醇、麦芽糊精、微晶纤维素、柠檬酸、硬脂酸镁。
叶黄素酯是叶黄素与多种不饱和脂肪酸所形成的酯,它丰富地存在于植物中,以万寿菊中含量最高。它是黄斑点色素的重要构成和抗氧化成分,是在眼睛中发现的唯一类胡萝卜素,进入人体内后,在脂肪酶作用下通过代谢水解成叶黄素进入血液,能够有效吸收损害人类视网膜的蓝光。叶黄素具有预防白内障、缓解视疲劳的作用,被称为“眼黄金”,是太阳高能蓝光的过滤器,保护眼部的视网膜被损坏,又是视网膜的抗氧化剂;氧化、光损伤也是造成老年性黄斑变性(AMD)和白内障的主要原因。许多眼科疾病都与叶黄素的缺乏有很大关系,但叶黄素和叶黄素酯在人体内无法合成,所以适当补充叶黄素和叶黄素酯能有效保护眼部视网膜和预防白内障。
蓝莓果实中含大量的花色苷、原花青素、类黄酮、超氧化物歧化酶(SOD)、熊果酸、维生素和矿物质元素等营养及生理活性成分,其抗氧化能力很强,具有促进视红素再合成、抗炎症、提高免疫力、抗心血管疾病、抗衰老、抗癌等多种生理功效,在食品、医药、健康产品等领域中应用已经是热点和焦点之一。Matsumoto等研宄发现浆果提取物中的花青素,尤其是矢车菊素-3-O-葡萄糖苷,能有效缓解视力疲劳,并有效提高人眼对强光和暗光的适应能力及能有效改善视觉瞬间适应性。宋雪等研究光对人视网膜色素上皮细胞损伤的影响,揭示了蓝莓花青素对人视网膜色素上皮细胞损伤的保护机制,结果表明蓝莓花青素能显著降低因氧化造成的hREP细胞损伤,且花青素的浓度越大,对hREP细胞损伤程度越低。孔祥强等研究发现蓝莓花青素能降低因过量自由基导致的晶状体蛋白氧化和显著降低白内障、晶体混浊和视网膜病变的发病率。蓝莓提取物中的花色苷可激活视网膜酶,起到活化和促进视红素合成的作用,提高人眼视觉上的敏锐程度,且使得人的视觉可以快速地适应黑暗环境,从而增强人的视力。
D-甘露糖醇是一种低热量功能性甜味剂,可作保湿剂,营养增补剂及组织改良剂。其本身口感比较好,不会影响食品的味道,如果食品中略有苦味,甜味剂还可以改善苦味。
功能性甜味剂有以下几个特点:(1)热量比较低,很难消化。主要源于甜味剂进入人体后代谢产生的热量值比较少,消化的途径与胰岛素没有任何关系,所以糖尿病人、高血压患者以及肥胖病人等都可以使用;(2)可以改善肠道功能,主要源于功能性甜味剂能够促进肠道内双歧杆菌的增殖,并在人体肠道内产生双歧杆菌,产生断链脂肪酸和一些抗菌素物质,对致病菌和腐败菌的生长繁殖有一定的抑制作用,增加肠道蠕动,改善便秘情况;(3)还具有抗龋齿的作用,功能性甜味剂中的低聚糖和糖醇等不会滋养口腔细菌,还能抑制突变链球菌的生长,所以长期食用甜味剂食品不会引起牙齿的龋齿情况。
作为一种优选的技术方案,各组分的重量份数为:叶黄素酯5~30%、蓝莓粉10~60%、D-甘露糖醇10~70%、麦芽糊精5~30%、微晶纤维素0~10%、柠檬酸0~1.5%、硬脂酸镁0~1%。
作为一种优选的技术方案,各组分的重量份数为:叶黄素酯5~25%、蓝莓粉10~50%、D-甘露糖醇20~60%、麦芽糊精5~28%、微晶纤维素1~10%、柠檬酸0.2~1.3%、硬脂酸镁0.2~1%。
作为一种优选的技术方案,各组分的重量份数为:叶黄素酯5~20%、蓝莓粉10~40%、D-甘露糖醇20~55%、麦芽糊精5~25%、微晶纤维素2~10%、柠檬酸0.2~1%、硬脂酸镁0.3~1%。
作为一种优选的技术方案,所述叶黄素酯为取自万寿菊的叶黄素酯或叶黄素酯微囊粉。
作为一种优选的技术方案,所述叶黄素酯中的叶黄素二棕榈酸酯质量百分比含量大于6%。
本发明第二方面在于提供一种所述缓解视疲劳的蓝莓叶黄素酯压片糖果的制备方法,包括以下步骤:
(1)过筛:将除柠檬酸之外的原料组分过40~60目筛,将柠檬酸过60~80目筛,备用;
(2)混合:将除叶黄素酯、硬脂酸镁、柠檬酸、麦芽糊精之外的原料组分按照重量份数加入,将柠檬酸用麦芽糊精进行等量梯度加法稀释3次后加入,再加入剩余的麦芽糊精,并充分混合均匀;
(3)制软材:加入水或醇水混合物制软材;
(4)制粒:将软材过筛造粒,干燥颗粒,摇摆制粒机整粒,并再次干燥颗粒;
(5)向所制备的颗粒中加入叶黄素酯和硬脂酸镁,充分混合均匀,压片制得所述蓝莓叶黄素酯压片糖果。
所述制得的蓝莓叶黄素酯压片糖果每片重约为0.5g,食用者可以采用嚼服或吞服等方式服用。本压片糖果采用当前接受度普遍较高的日常零食品方式,方便食用及携带,并具有良好的口感,通过叶黄素酯微囊粉、蓝莓粉等原料组分的协同配合作用,能够显著缓解视疲劳。
本发明结合营养学,采用天然原料,例如采用人体内不能合成的叶黄素酯,采用蓝莓粉提供天然的花色苷等,这些原料组分不仅各自对视力有较好的保护功能,联合使用后各成分相互协同作用,能够促进原料之间的有效缓解视疲劳的效果,能够增强患者的抗视疲劳能力,从根本上解决视疲劳问题。叶黄素酯、蓝莓粉进行更科学合理比例搭配后,协同效果更强,可以更显著地提高缓解视疲劳。添加适量比例的功能性甜味剂D-甘露糖醇、柠檬酸调配出优良的口感,再添加少量其它加工助剂等辅料进行高产率制备,制备方法操作简单,流程简化,便于大规模工业化生产应用,从而得到集营养与保健为一体,兼具优良口感的具有缓解视疲劳功效的压片糖果,非常适合长期使用电脑者、青少年人群、中老年人群和夜间工作者等用眼过度人群和亚健康人群服用。糖果原料天然,食用安全,无副作用,口感优良,功效显著,便于携带,加之目前国内具有护眼功能的压片糖果产品较少,该产品可有效填补市场空间的不足,具有良好的应用前景。
具体实施方式
下面结合实施例对本发明作进一步详细的描述,但本发明的实施方式不限于此。在未作说明的情况下,本发明所采用的试剂、设备和方法均为本技术领域常规市购的试剂、设备和常规使用的方法。
实施例1:
一种缓解视疲劳的蓝莓叶黄素酯压片糖果,按重量份数计,包括以下组分:叶黄素酯10%、蓝莓粉40%、D-甘露糖醇27%、麦芽糊精20%、微晶纤维素2%、柠檬酸0.5%、硬脂酸镁0.5%。
制备方法包括以下步骤:
(1)过筛:将除柠檬酸之外的原料组分过40目筛,将柠檬酸过60目筛,备用;
(2)混合:将除叶黄素酯、硬脂酸镁、柠檬酸、麦芽糊精之外的原料组分按照重量份数加入,将柠檬酸用麦芽糊精进行等量梯度加法稀释3次后加入,再加入剩余的麦芽糊精,并充分混合均匀;
(3)制软材:加入水或醇水混合物制软材;
(4)制粒:将软材过筛造粒,干燥颗粒,摇摆制粒机整粒,并再次干燥颗粒;
(5)向所制备的颗粒中加入叶黄素酯和硬脂酸镁,充分混合均匀,压片制得所述蓝莓叶黄素酯压片糖果。
实施例2:
一种缓解视疲劳的蓝莓叶黄素酯压片糖果,按重量份数计,包括以下组分:叶黄素酯15%、蓝莓粉30%、D-甘露糖醇35%、麦芽糊精13.7%、微晶纤维素5%、柠檬酸0.8%、硬脂酸镁0.5%。
制备方法与实施例1相同,在此不赘述。
实施例3:
一种缓解视疲劳的蓝莓叶黄素酯压片糖果,按重量份数计,包括以下组分:叶黄素酯12%、蓝莓粉35%、D-甘露糖醇36.7%、麦芽糊精10%、微晶纤维素5%、柠檬酸0.8%、硬脂酸镁0.5%。
制备方法与实施例相同,在此不赘述。
实施例4:
一种缓解视疲劳的蓝莓叶黄素酯压片糖果,按重量份数计,包括以下组分:叶黄素酯15%、蓝莓粉40%、D-甘露糖醇30%、麦芽糊精11.5%、微晶纤维素2%、柠檬酸0.9%、硬脂酸镁0.6%。
制备方法与实施例1相同,在此不赘述。
实施例5:
一种缓解视疲劳的蓝莓叶黄素酯压片糖果,按重量份数计,包括以下组分:叶黄素酯11.5%、蓝莓粉37%、D-甘露糖醇30%、麦芽糊精13.2%、微晶纤维素7%、柠檬酸0.8%、硬脂酸镁0.5%。
制备方法与实施例1相同,在此不赘述。
效果实施例1:
采用实施例1制得的蓝莓叶黄素酯压片糖果作为样品进行人群试食实验,评价产品缓解视疲劳的实际效果。
1.受试人群筛选
人群要求:18~65岁的成年人,长期用眼,视力易疲劳者。
受试人群排除标准:排除患有感染性、外伤性眼部疾患者,进行眼部手术不足3个月者,患有角膜、晶体、玻璃体、眼底病变等内外眼疾患者,短期内服用与受试功能有关的物品影响到对结果的判定者,长期服用有关治疗视力的药物、保健品或使用其它治疗方法未能终止者。
共招募受试者45人,年龄介于20~63岁,其中男性19人,女性26人。
2.样品的剂量和使用方法
样品服用方法为每日口服两片,服用时间为连续30天。
3.功效判定标准
详见下表1,眼酸痛、眼胀、畏光、视物模糊、眼干涩、异物感、流泪、全身不适8种症状中有3种改善(症状积分降低),且其它症状无恶化即判定症状改善。症状改善有效率(%)计算方法为症状改善例数/试食例数×100%。
表1-视疲劳症状判定方法
注:“偶感”是指1~2次/2天;“时有”是指1~3次/天;“经常”是指>3次/天。
4.人群试食实验结果
服用蓝莓叶黄素酯压片糖果连续30天后,对受试人群的症状改善情况进行统计,症状改善例数为37例,症状改善有效率达到82.2%,说明本发明的蓝莓叶黄素酯压片糖果具有显著的改善视疲劳的作用。
以上所述,仅为本发明的较佳的具体实施例,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其构思加以等同替换或改变,都应涵盖在本发明的保护范围内。
Claims (7)
1.一种缓解视疲劳的蓝莓叶黄素酯压片糖果,其特征在于,包括以下组分:叶黄素酯、蓝莓粉、D-甘露糖醇、麦芽糊精、微晶纤维素、柠檬酸、硬脂酸镁。
2.根据权利要求1所述的缓解视疲劳的蓝莓叶黄素酯压片糖果,其特征在于,各组分的重量份数为:叶黄素酯5~30%、蓝莓粉10~60%、D-甘露糖醇10~70%、麦芽糊精5~30%、微晶纤维素0~10%、柠檬酸0~1.5%、硬脂酸镁0~1%。
3.根据权利要求1所述的缓解视疲劳的蓝莓叶黄素酯压片糖果,其特征在于,各组分的重量份数为:叶黄素酯5~25%、蓝莓粉10~50%、D-甘露糖醇20~60%、麦芽糊精5~28%、微晶纤维素1~10%、柠檬酸0.2~1.3%、硬脂酸镁0.2~1%。
4.根据权利要求1所述的缓解视疲劳的蓝莓叶黄素酯压片糖果,其特征在于,各组分的重量份数为:叶黄素酯5~20%、蓝莓粉10~40%、D-甘露糖醇20~55%、麦芽糊精5~25%、微晶纤维素2~10%、柠檬酸0.2~1%、硬脂酸镁0.3~1%。
5.根据权利要求1所述的缓解视疲劳的蓝莓叶黄素酯压片糖果,其特征在于,所述叶黄素酯为取自万寿菊的叶黄素酯或叶黄素酯微囊粉。
6.根据权利要求1所述的缓解视疲劳的蓝莓叶黄素酯压片糖果,其特征在于,所述叶黄素酯中的叶黄素二棕榈酸酯质量百分比含量大于6%。
7.一种如权利要求1~6任一项所述的缓解视疲劳的蓝莓叶黄素酯压片糖果的制备方法,其特征在于,包括以下步骤:
(1)过筛:将除柠檬酸之外的原料组分过40~60目筛,将柠檬酸过60~80目筛,备用;
(2)混合:将除叶黄素酯、硬脂酸镁、柠檬酸、麦芽糊精之外的原料组分按照重量份数加入,将柠檬酸用麦芽糊精进行等量梯度加法稀释3次后加入,再加入剩余的麦芽糊精,并充分混合均匀;
(3)制软材:加入水或醇水混合物制软材;
(4)制粒:将软材过筛造粒,干燥颗粒,摇摆制粒机整粒,并再次干燥颗粒;
(5)向所制备的颗粒中加入叶黄素酯和硬脂酸镁,充分混合均匀,压片制得所述蓝莓叶黄素酯压片糖果。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011601006.6A CN112715729A (zh) | 2020-12-30 | 2020-12-30 | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011601006.6A CN112715729A (zh) | 2020-12-30 | 2020-12-30 | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112715729A true CN112715729A (zh) | 2021-04-30 |
Family
ID=75611599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011601006.6A Pending CN112715729A (zh) | 2020-12-30 | 2020-12-30 | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112715729A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113796534A (zh) * | 2021-09-15 | 2021-12-17 | 沃德绿世界(溧水)生物科技有限公司 | 一种蓝莓叶黄素酯片和生产工艺及其设备 |
CN115251212A (zh) * | 2022-06-23 | 2022-11-01 | 衍生健康医药(广东)有限公司 | 一种蓝莓叶黄素酯压片糖果及其制备方法 |
CN116369413A (zh) * | 2022-12-26 | 2023-07-04 | 甘肃省轻工研究院有限责任公司 | 一种三黄护眼糖果片的制备方法 |
CN117063995A (zh) * | 2023-08-23 | 2023-11-17 | 陕西朗目视家健康科技有限公司 | 一种叶黄素酯果蔬压片糖果及制备方法 |
CN117121968A (zh) * | 2023-08-01 | 2023-11-28 | 南昌大学 | 一种茶皂素蓝莓压片糖果及其制备方法和应用 |
WO2024055795A1 (zh) * | 2022-09-16 | 2024-03-21 | 大连工业大学 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104397311A (zh) * | 2014-11-28 | 2015-03-11 | 哈尔滨墨医生物技术有限公司 | 一种缓解视疲劳的蓝莓复合压片糖果及其制备方法 |
CN108157568A (zh) * | 2017-12-29 | 2018-06-15 | 广东粤微食用菌技术有限公司 | 一种缓解视疲劳的组合糖果及其制备方法和用途 |
CN109845868A (zh) * | 2018-12-14 | 2019-06-07 | 西安极客食品有限公司 | 一种改善视疲劳的叶黄素酯压片糖果及其制备方法 |
CN110169484A (zh) * | 2019-04-23 | 2019-08-27 | 广东润源中天生物科技有限公司 | 一种蓝莓叶黄素酯压片糖果及其制备方法 |
CN111227097A (zh) * | 2020-02-27 | 2020-06-05 | 山东祥宏堂医药有限公司 | 一种蓝莓叶黄素酯糖果片剂及制备方法 |
-
2020
- 2020-12-30 CN CN202011601006.6A patent/CN112715729A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104397311A (zh) * | 2014-11-28 | 2015-03-11 | 哈尔滨墨医生物技术有限公司 | 一种缓解视疲劳的蓝莓复合压片糖果及其制备方法 |
CN108157568A (zh) * | 2017-12-29 | 2018-06-15 | 广东粤微食用菌技术有限公司 | 一种缓解视疲劳的组合糖果及其制备方法和用途 |
CN109845868A (zh) * | 2018-12-14 | 2019-06-07 | 西安极客食品有限公司 | 一种改善视疲劳的叶黄素酯压片糖果及其制备方法 |
CN110169484A (zh) * | 2019-04-23 | 2019-08-27 | 广东润源中天生物科技有限公司 | 一种蓝莓叶黄素酯压片糖果及其制备方法 |
CN111227097A (zh) * | 2020-02-27 | 2020-06-05 | 山东祥宏堂医药有限公司 | 一种蓝莓叶黄素酯糖果片剂及制备方法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113796534A (zh) * | 2021-09-15 | 2021-12-17 | 沃德绿世界(溧水)生物科技有限公司 | 一种蓝莓叶黄素酯片和生产工艺及其设备 |
CN115251212A (zh) * | 2022-06-23 | 2022-11-01 | 衍生健康医药(广东)有限公司 | 一种蓝莓叶黄素酯压片糖果及其制备方法 |
WO2024055795A1 (zh) * | 2022-09-16 | 2024-03-21 | 大连工业大学 | 一种具有抵御视网膜蓝光损伤的药食两用组合物及其制备方法与应用 |
CN116369413A (zh) * | 2022-12-26 | 2023-07-04 | 甘肃省轻工研究院有限责任公司 | 一种三黄护眼糖果片的制备方法 |
CN117121968A (zh) * | 2023-08-01 | 2023-11-28 | 南昌大学 | 一种茶皂素蓝莓压片糖果及其制备方法和应用 |
CN117063995A (zh) * | 2023-08-23 | 2023-11-17 | 陕西朗目视家健康科技有限公司 | 一种叶黄素酯果蔬压片糖果及制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112715729A (zh) | 一种缓解视疲劳的蓝莓叶黄素酯压片糖果及其制备方法 | |
Kumar et al. | Traditional and medicinal uses of banana | |
CN103735733B (zh) | 一种含叶黄素酯的复方制剂及其制备方法 | |
CN108157568A (zh) | 一种缓解视疲劳的组合糖果及其制备方法和用途 | |
US20090297618A1 (en) | Composition beneficial for visuognosis persistence and use thereof | |
CN109619566A (zh) | 一种缓解视力疲劳的营养食品 | |
CN107951955A (zh) | 一种缓解眼疲劳的复方组合物 | |
US20210046003A1 (en) | Health drink composition for preventing liver damage caused by alcohol while providing excellent hangover relief | |
CN101564160A (zh) | 防治高血脂高血糖的食品及其制备方法 | |
CN100486456C (zh) | 一种用于缓解视疲劳的保健食品及其制备方法 | |
KR102571939B1 (ko) | 테트라셀미스 츄이를 유효성분으로 포함하는 안구건조질환 개선용 조성물 | |
EP3570862B1 (en) | Compositions based on active principles of plants origin having eye protection action | |
CN115956670A (zh) | 缓解视疲劳组合物、制剂及制备方法和用途 | |
CN108354918A (zh) | 含茶氨酸、γ-氨基丁酸和原花青素的缓解视疲劳的组合物 | |
CN105685317A (zh) | 富含硒火麻茶及其制备方法 | |
CN101982086A (zh) | 一种叶黄素口香糖及其制备方法 | |
CN108042652A (zh) | 含枸杞、菊花和γ-氨基丁酸的缓解视疲劳的组合物 | |
CN101785854B (zh) | 叶黄素多维营养保健药物组合物、其制备方法及应用 | |
CN102150860B (zh) | 一种用于缓解视疲劳和辅助改善记忆的组合物 | |
CN108324705A (zh) | 含茶氨酸、γ-氨基丁酸和花青素的缓解视疲劳的组合物 | |
CN108261472A (zh) | 含枸杞、菊花、γ-氨基丁酸和茶氨酸的缓解视疲劳的组合物 | |
CN112913957A (zh) | 一种护肝的盐藻压片糖果及其制备方法 | |
CN112006282A (zh) | 一种修复糖尿病并发症的组合物及其制备方法与应用 | |
CN115251217A (zh) | 一种缓解视疲劳压片糖果及其制备方法与应用 | |
CN105101817B (zh) | 可食用组合物及其制备方法和包含该组合物的食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210430 |
|
RJ01 | Rejection of invention patent application after publication |